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In cancer, immune cells can play conflicting roles,
either protective, by elimination of tumor cells during
immune surveillance, or detrimental, by promoting
carcinogenesis during inflammation. We report here
that the thymus-specific serine protease (TSSP),
which is involved in CD4+ T cell maturation in the
thymus, exerts a tumor suppressor activity. Mice
genetically deficient for TSSP are highly prone to
spontaneous cancer development. The absence of
TSSP also increases the rate of induced colitis-asso-
ciated colorectal (CAC) tumor formation, through
exacerbated colon inflammation. Adoptive transfer
of T cells in various combinations (CD4+ and CD8+
fromwild-type and/or knockoutmice) into T cell-defi-
cient mice showed that the TSSP-deficient CD4+
T cell compartment promotes tumor development,
associated with high levels of the cytokine IL-17A.
Inhibition of IL-17A during CAC tumor formation
prevents the increased carcinogenesis and colic im-
mune disequilibrium observed in TSSP-deficient
mice. Therefore, our data demonstrate that antitu-
moral immune surveillance requires thymic TSSP-
driven production of CD4+ T cells contributing to
inflammatory balance.INTRODUCTION
One of the currently promising strategies in cancer treatment
is immunotherapy, which consists in targeting the immune
response in order to favor the elimination of cancer cells (Cou-
zin-Frankel, 2013; Dougan and Dranoff, 2009; Mellman et al.,
2011; Muranski and Restifo, 2009). During cancer development,
immune cells appear to prevent the emergence of tumoral cells
and inhibit cancer progression through the so-called immune
surveillance (Dunn et al., 2004; Swann and Smyth, 2007). Never-theless, immunity (both innate and adaptive) can also promote
tumor development during inflammation; hence, chronic inflam-
matory diseases favor the growth of many human cancers (Bui
and Schreiber, 2007; de Visser et al., 2006; Kundu and Surh,
2012; Trinchieri, 2012). Thus, the role of adaptive immune cells
is dual, depending on the context and cell types; in particular,
CD4 (T helper) lymphocytes can either impair or favor carcino-
genesis (Corthay et al., 2005; DeNardo et al., 2009; Kennedy
and Celis, 2008; Ostrand-Rosenberg, 2008; Rakhra et al., 2010).
Inflammatory bowel disease (IBD) patients are at increased
risk of developing colorectal cancer (CRC). In CRC, on one
side, T cells have been elegantly shown to be protective against
cancer progression, through their antitumor effect in eliminating
cancerous cells (Page`s et al., 2005). On the other side, T cells
participate during IBD in the protumoral inflammatory reaction
stimulating uncontrolled growth of epithelial cancer cells (Monte-
leone et al., 2012).
We recently reported the importance of the thymus-specific
serine protease (TSSP) in T cell maturation in the thymus. TSSP
is encoded by the PRSS16 gene, which is highly conserved be-
tween humans and mice (Bowlus et al., 1999; Carrier et al.,
1999, 2000). TSSP is a serine protease of yet-unknown enzymatic
function, predominantly found in endosomes of thymic cortical
epithelial cells. TSSPwas first reported as linked to a type 1 (auto-
immune) diabetes (T1D) susceptibility locus of the extended ma-
jor histocompatibility complex class I region in humans (Lie et al.,
1999, 2002; Viken et al., 2009). To address the function of TSSP,
we generated a genetically inactivatedmousemodel (TSSP-defi-
cient mice, hereafter called TSSP KO). In-depth analysis of these
mice showed that they have a normal number of CD4+ T cells but
an altered T cell receptor repertoire (Gommeaux et al., 2009; Viret
et al., 2011a).Moreover, the absenceof TSSP on a nonobese dia-
betes background completely prevents the development of T1D,
thus demonstrating the direct implication of TSSP in disease
development (Viret et al., 2011b). Prevention of T1D development
in the absence of TSSP is related to impaired thymic selection of
CD4+ T cells specific for islet antigens (Viret et al., 2011b). Thus,
our previous work evidenced a crucial role of TSSP in the shaping
of a functional CD4+ T cell compartment. To date, the impact of
TSSP in cancer has not yet been investigated. In thymic tumors,Cell Reports 10, 39–46, January 6, 2015 ª2015 The Authors 39
Figure 1. TSSP Deficiency Favors CAC
Tumorigenesis
Cohorts of 8- to 10-week-old WT and TSSP-defi-
cient mice (n = 36 and 24, respectively) were
treated with a single injection of AOM, followed by
three cycles of DSS (2.5% during 5 days, except
2%during 4 days in the last cycle) in drinkingwater
to induce a moderate, long-lasting colitis.
(A) Scheme of the CAC (AOM DSS) protocol.
Colons are collected 10 weeks after injection of
AOM and analyzed for the presence of tumors.
(B) Mean number ± SD of tumors and their size
distribution per colon fromWT and TSSP-deficient
(KO) animals (**p < 0.01).
(C) Mean ± SD of the weight-to-length ratios of the
colons (mg/mm). The dashed line corresponds to
the mean weight-to-length ratio of control animals
(***p < 0.001). The total number of animals is
combined from three independent experiments,
and data are representative of two different ex-
periments.
(D and E) Overview of hematoxylin and eosin-
stained sections of representative colons fromWT
(D) and TSSP-deficient mice (E). Representative
tumors are shown for each genotype. Scale bar
corresponds to 100 mm.TSSP was reported to be either over- or underexpressed, de-
pending on the cell type affected by cancerous proliferation (cor-
tex thymoma or thymic lymphoma, respectively) (Lin and Aplan,
2007; Strobel et al., 2014). During breeding of TSSP-deficient
mice, we serendipitously observed spontaneous cancer devel-
opment upon aging. In the current work, we assessed the con-
sequence of TSSP deficiency on mouse cancer pathology and
unveiled the associated mechanisms.
RESULTS AND DISCUSSION
TSSP-Deficient Mice Are Highly Susceptible to
Both Spontaneous Cancer Development and
Inflammation-Associated Cancer
We first addressed the question of the lifespan of TSSP-deficient
mice compared to wild-type (WT) by checking mice survival
during aging over a 3-year period. While the lifespan of TSSP-
deficient mice did not differ from that of TSSP-proficient mice
(Figure S1A), we observed spontaneous tumor development in
aged TSSP-deficient mice. Indeed, 100% of TSSP KO mice
died from cancer development, either hepatocarcinoma (HCC)
or lymphoma (Figures S1B and S1C). C57BL/6 mice are known
to rarely develop cancer, unless on an immunodeficient back-
ground (Swann and Smyth, 2007). Our observation suggests
that absence of TSSP generates a permissive environment for
spontaneous tumor development, potentially through a partial
immunodeficiency.
In order to decipher the mechanistic basis of increased
susceptibility of TSSP KOmice to cancer, we used an inflamma-
tion-induced tumorigenesis setting. The colitis-associated colo-
rectal cancer (CAC) protocol consists of an intraperitoneal (i.p.)
injection of azoxymethane (AOM), which initiates tumorigenesis,
followed by three cycles of dextran sodium sulfate (DSS) in the
drinking water, inducing a chronic colitis, which promotes the40 Cell Reports 10, 39–46, January 6, 2015 ª2015 The Authorsdevelopment of colorectal tumors (Figure 1A). One hundred
percent of mice developed colon tumors in this protocol, what-
ever their genotype. Strikingly, we observed a higher number
of tumors in the colon of TSSPKOas compared toWTmice, spe-
cifically a higher number of large tumors (Figure 1B). Conse-
quently, colon weight gain was higher in TSSP KO mice than in
WTmice (Figure 1C). Histological analysis showed that these tu-
mors are adenoma with a high grade of dysplasia in both geno-
types (Figures 1D and 1E), as is the case in this induced CAC
model (Gommeaux et al., 2007; Neufert et al., 2007). Those
data show that the susceptibility of TSSP KO mice to cancer is
also observed in a tumor-induced experimental setting.
More Severe Inflammation in TSSP-Deficient Mice Than
in WT Likely Accounts for Increased Colitis-Associated
Tumorigenesis
As inflammation is a major factor of CAC development, we
induced acute colitis by adding 3.5% DSS in the drinking water
of TSSP KO and WT mice for 7 days. We observed higher body
weight loss, mortality, disease activity index (which combines
stool consistency, rectal bleeding, and weight loss), and mu-
cosal ulcerations in TSSPKOas compared toWTmice (Figure 2).
Thus, DSS-induced acute colitis is more severe in TSSP-defi-
cient as compared to TSSP-proficient mice. This result suggests
that regulation of acute inflammation is altered in the absence
of TSSP, proposing a role for TSSP in inflammation control.
Exacerbated DSS-induced chronic inflammation during the
CAC protocol could explain increased colorectal tumors devel-
opment in the absence of TSSP.
T Cells Play a Key Role in Increased CAC in the
Absence of TSSP
The increased CAC development in TSSP-deficient mice could
result from a defect in either epithelial cells (which give rise to
Figure 2. Absence of TSSP Increases
Severity of DSS-Induced Acute Colitis
Cohorts of 8- to 10-week-old mice were given
3.5% DSS in their drinking water for 7 days
(gray bar) to induce acute colitis and then tap
water without DSS up to the end of the exper-
iment.
(A) Weight loss is expressed as a percentage of
the initial weight at day 0. TSSP-deficient mice
(KO, full symbol, n = 14) lost more weight than WT
mice (empty symbol, n = 18).
(B) Survival curve showing a higher mortality after
induction of colitis in TSSP-deficient than in WT
mice.
(C) The disease activity index (mean ± SD)
increased to higher values in TSSP-deficient mice
than in WT mice.
For (A) and (C), from one to three; asterisks indi-
cate p values of 0.05, 0.01, and 0.001, respec-
tively, when comparing TSSP-deficient and WT
mice.
(D and E) Microscopic examination of colon
sections 7 days after the induction of colitis shows
more extensive ulceration (indicated by the
black line) in TSSP-deficient animals (E) than in
WT mice (D).
(F and G) Histological analysis at higher magnification (3200) shows moderate epithelium damage in WT mice, with a progressive disappearance of glands (F).
Damage is more severe in TSSP-deficient animals (G). Data are representative of three independent experiments.colorectal tumors) or from immune system function (which is
involved in epithelial barrier homeostasis). We previously re-
ported that the Prss16 gene encoding TSSP in mouse is highly
expressed in cortical thymic epithelial cells, a feature also re-
ported in humans (Bowlus et al., 1999; Carrier et al., 1999). We
investigated Prss16 expression in other tissues, including colon,
by quantitative RT-PCR experiments. Contrary to thymic stroma,
where TSSP expression was very high, very little mRNA was de-
tected in liver (both hepatocytes and nonparenchymatous [im-
mune] cells), spleen, macrophages, and colon intraepithelial
cells of unchallenged or CAC (AOM DSS) mice (Figure S2A).
Thus, we propose that TSSP expression is specific to the thymic
stromal microenvironment and postulate that higher CAC sus-
ceptibility of TSSP KO mice stems from immune cell defects
acquired during thymic development rather than from colon
epithelial cell deregulation.
To investigate the specific role of immune cells in increased
CAC susceptibility of TSSP-deficient mice, we used immunode-
ficient mice. We crossed TSSP KO with CD3 epsilon delta 5
(named here CD3 KO)-deficient mice, which are specifically
devoid of T lymphocytes (Malissen et al., 1995). Development
of CAC was similar in CD3 KO mice as compared to WT mice
(Figure 3A). In addition, contrary to what was observed in
TSSP KO mice as compared to WT, the number of CAC tumors
was not increased in double-KO mice as compared to CD3 KO
(Figure 3A). These data suggest that the role of TSSP on CAC
is mediated by T lymphocytes as initially postulated. To formally
demonstrate this hypothesis, we performed T cell adoptive
transfer experiments in CD3 KO recipient mice. The presence
of T cells in CD3 KO recipients was checked during the course
of, and at the end of, the experiment (Figure S2B). Data reported
in Figure 3B show that (1) the presence of T cells in CD3 KOrecipient mice increases the number and size of CAC tumors
and (2) development of CAC tumors is higher when the injected
T cells were purified from TSSP KO mice than from WT.
As cytokines are primary molecular mediators of immune cells
that can be either protective or permissive in CAC (Waldner and
Neurath, 2009), we monitored the expression of Th cytokines
(interleukin-10 [IL-10], IL-4, interferon g [IFN-g], IL-17A) in the co-
lon of mice by quantitative RT-PCR. Interestingly, the levels of
IFN-g (the signature of antitumoral Th1 cells) and anti-inflamma-
tory IL-10 are lower in TSSP KOmice than inWTmice (Figure 3C,
left). In contrast, level of IL-4 (the signature of protumoral Th2
cells) is high in CD3 KO recipient mice injected with TSSP KO
T cells (Figure 3C, right). Strikingly, the expression level of protu-
moral IL-17A is high when T cells are deficient for TSSP both in a
CD3 WT background (Figure 3C, left) and in a CD3 KO back-
ground upon adoptive transfer (Figure 3C, right). Taken together,
these data show that absence of TSSP is associated with a pro-
tumoral Th cytokine profile.
CD4+ T Cells Are Pivotal in Increased CAC in the
Absence of TSSP
We previously demonstrated that TSSP is involved in the matu-
ration of a subset of CD4+ T cells (Gommeaux et al., 2009; Viret
et al., 2011a, 2011b). We therefore sought to gain further insight
into the role of CD4+/CD8+ T cells in CAC development by per-
forming adoptive transfer experiments using a mixture of CD4+
and CD8+ T cells (purified from either TSSP KO or WT mice) in-
jected in CD3 KO recipient mice. As observed in the preceding
experiment, the presence of T cells in CD3 KO mice gave rise
to increased numbers of CAC tumors (Figure 3D). Strikingly,
whenCD4+ T cells were purified from TSSPKOmice, the number
and size of CAC tumors were much higher than with CD4+ cellsCell Reports 10, 39–46, January 6, 2015 ª2015 The Authors 41
Figure 3. T Cells Play a Key Role in
Increased CAC in the Absence of TSSP
The impact of TSSP deficiency on T lymphocytes
during CAC development was evaluated in CD3ε-
deficient mice (CD3 KO) lacking T lymphocytes.
(A and B) CAC tumors mean number ± SD and size
distribution per colon depending onmice genotype
(n = 21–36). (A) Difference between TSSP-deficient
and WT mice is abolished in a T lymphocyte-defi-
cient background (* and $, compared to WT and
TSSP KO, respectively). DKO, double KO. (B)
Adoptive transfer of T lymphocytes isolated from
WT or TSSP-deficient mice in CD3 KO recipient
mice (n = 16 for each group). The difference be-
tween the two genotypes is recovered upon
adoptive transfer of T lymphocytes (*, compared to
noninjected CD3 KO; $, compared to CD3 KO in-
jected with WT T lymphocytes).
(C) Expression of cytokines (mean ± SD) in total
tumoral colons was evaluated by quantitative RT-
PCR and compared between TSSP-deficient and
WT mice on a CD3 WT background (left) or a CD3
KO background (middle) and in CD3 KO mice in-
jected with T lymphocytes (right).
From one to three, marks indicate p values less
than 0.05, 0.01, and 0.001, respectively. Data are
representative of independent experiments (six for
A and two for B).
(D and E) Adoptive transfer of mix of CD4+ and
CD8+ T lymphocytes isolated from WT or TSSP-
deficient mice in CD3 KO recipient mice (n = 7–16).
(D) CAC tumor mean number ± SD and size distribution per colon depending on the T cell genotype. * and $, compared to CD3 KO noninjected mice or CD3 KO
recipient mice injected with WT T cells, respectively. (E) Cytokine expression (mean ± SD) profile in total tumoral colons from adoptively transferred CD3 KO
recipient mice. The absence of TSSP in CD4 compartment induces a robust increase in IL-17A expression independently of CD8 genotype, either WT (left) or
TSSP deficient (right).
*Difference between WT and TSSP-deficient cells. Data are representative of three independent experiments.purified from WT mice. We also observed increased number of
large tumors when CD8+ T cells were purified from TSSP KO
mice; hence, we cannot exclude the impact of CD8+ T cells
that matured in a TSSP-deficient immune context on CAC devel-
opment. We then monitored the expression of cytokines in the
colon and observed robust IL-17A overexpression when CD4+
T cells are deficient for TSSP, irrespective of the CD8+ genotype
(Figure 3E). Finally, we quantified tumoral epithelial cells prolifer-
ation by Ki67 immunostaining on colon sections and observed
no significant differences between the different experimental
groups (Figure S3A). Taken together, these data suggest that
promotion of CAC development is not an epithelial-intrinsic
event linked to TSSP deficiency but rather results from extrinsic
signals from the inflammatory microenvironment containing
CD4+ T cells shaped in a TSSP-deficient thymus. This study
clearly points out a prominent overexpression of the protumoral
IL-17A cytokine in a TSSP-deficient immune context. Inter-
estingly, although the role of Th17 cytokines in cancer is dual
depending on the context, evidence of decreased CAC in IL-
17A-deficient mice strongly supports its protumoral role in the
colon (De Simone et al., 2013; Hyun et al., 2012).
Inhibition of IL-17A Prevents the Increase in CAC in the
Absence of TSSP
In order to assess the increased protumoral action of IL-17 in
TSSP-deficient colons, we treated mice with anti-IL-17A anti-42 Cell Reports 10, 39–46, January 6, 2015 ª2015 The Authorsbodies weekly during the CAC protocol. As a control, mice in-
jected with control isotype antibodies showed higher colon
tumor numbers and size when deficient for TSSP as compared
toWT, as is the case in all CAC experiments (Figure 4A). Remark-
ably, inhibition of IL-17A not only reduced tumor burden in the
two genotypes but also almost completely erased the difference
between both genotypes. This result strongly supports the key
role of IL-17A overexpression in exacerbated CAC in the
absence of TSSP. We monitored the expression of cytokines in
CAC colons in isolated tumoral and nontumoral (healthy) areas
(Figure 4B). Themain information provided by these experiments
is that (1) in control KO colons (control-isotype treated), anti-in-
flammatory cytokines (IL-10 and IFN-g) are reduced whereas
proinflammatory cytokines (IL-4 and IL-17A) are increased
compared toWT,which is consistentwith data shown in Figure 3;
(2) in control KO colons, the level of IL-4 and IL-17A is higher in
tumoral areas than in nontumoral areas; and (3) most impor-
tantly, differences between KO and WT colons are reduced or
completely abolished when mice are treated with anti-IL-17A
antibody. In parallel, we analyzed immune cells in secondary
lymphoid organs by flow cytometry (Figure 4C). No differences
were observed between the two genotypes, except for a signif-
icant decrease in the number of T regulatory (Treg) cells in the
spleen of control-isotype-treated CAC KO mice, which is abol-
ished upon anti-IL-17A treatment. This observation is interesting,
since Treg cells are known to play an antitumoral role in CAC by
Figure 4. Inhibition of IL-17A Cytokine Rescues the Phenotype of TSSP-Deficient Mice
Impact of IL-17A has been evaluated by the injection of either control isotype or blocking anti-IL-17A antibody during the course of CAC development.
(A) CAC tumor mean number ± SD and size distribution per colon depending on mice genotype and antibody injection (n = 5–9). Differences between TSSP-
deficient andWTmice are almost completely abolished when mice are injected with anti-IL-17A antibody. *, $, and £, compared to control WT, control TSSP KO,
and anti-IL-17A-treated WT mice, respectively.
(B) Expression of cytokines (mean ± SD) in sane and tumoral regions of colons was evaluated by quantitative RT-PCR and compared between TSSP-deficient
and WT mice injected with either control or anti-IL-17A antibody. From one to three, marks indicate p values less than 0.05, 0.01, and 0.001, respectively.
(C) Immune cell percentages (mean ± SD) in secondary lymphoid organs evaluated by flow cytometry. Except for splenic Tregs (*p < 0.05), no differences were
observed between WT and TSSP-deficient mice.
Data are representative of two independent experiments.dampening inflammation, in contrast with their more famous pro-
tumoral role by attenuating tumor immunosurveillance (Waldner
and Neurath, 2009). We also analyzed the same immune cells in
lymphoid organs from nonchallenged mice at different ages and
observed no differences, as previously reported (Gommeaux
et al., 2007; Viret et al., 2011b). Taken together, those data
show that neutralization of IL-17A alleviates the CAC susceptibil-
ity of TSSP-deficient mice by dampening cytokinic immune
disequilibrium in the colon.
To better characterize the colon immune disequilibrium asso-
ciated with TSSP deficiency, we analyzed immune cells in the
colon. We first analyzed lamina propria lymphocytes (LPLs) inthe colons of nonchallenged mice and observed no differences
between the two genotypes (data not shown). In contrast, the im-
mune cell content (LPLs + tumor-infiltrating lymphocytes [TILs])
of CAC-induced colons differed between genotypes (Figure S4).
Figure S4A shows flow cytometry analysis of immune cells in the
colon of CAC-induced anti-IL-17A-treated mice as compared to
control-treated mice. The numbers of CD8+ T cells and granulo-
cytes were decreased in control KO colons as compared to WT;
these differences are completely abolished upon IL-17A inhibi-
tion. Interestingly, IL-17A inhibition leads to a slight decrease
of (likely protumoral) CD4+ T cell numbers in KO colons. We
also analyzed immune cells in isolated tumoral and healthy areasCell Reports 10, 39–46, January 6, 2015 ª2015 The Authors 43
of CAC colons (Figure S4B). In WT colons, immune cells are
spread throughout the whole colon (except granulocytes, which
are enriched in areas containing tumors, as is the case in KO
mice). In contrast, in KO colons, tumoral regions contain less
CD8+ T cells and more Tregs than healthy areas. Most impor-
tantly, cancer colons contained numerous IL-17-secreting im-
mune cells (not only CD4+ Th17 cells), with an increase of those
cells in the healthy (peritumoral) areas of KO colons. These data
are consistent with immunohistofluorescence data (Figure S3B),
which nicely show a decrease in CD8+ T cell numbers in KO co-
lon tumors and prominent accumulation of IL-17+ cells in peritu-
moral areas of KO colons. IL-17A is known to be secreted by
several cell types (Th17, gd T, innate lymphoid cells, natural killer
T cells, and neutrophils), which all play a role in carcinogenesis
(De Simone et al., 2013). Altogether, these data show that both
the percentage of different immune cell types and their tissue
localization are affected in the colon of TSSP-deficient mice in
the CAC context, showing that TSSP deficiency is associated
with immune response disequilibrium during CAC, thus gener-
ating an unfavorable ‘‘anticancer immune contexture’’ (Fridman
et al., 2012). This defect is rescued by inhibition of IL-17A, thus
demonstrating the prominent role of IL-17 in high CAC suscepti-
bility in a TSSP-deficient immune environment. This study there-
fore further stresses the crucial role of IL-17-producing cells in
colorectal cancer development and contributes to the elucida-
tion of immune mechanisms.
In conclusion, this work demonstrates that the cancer sus-
ceptibility of TSSP KO mice results from an altered CD4+ T cell
compartment and loss of cytokine balance. In CAC, the absence
of TSSP is associatedwith increased protumoral IL-17 responses.
Interestingly, the Th17 response has beenassociatedwith promo-
tion of colorectal development in mice and a poor prognosis in
colorectal cancer patients (Tosolini et al., 2011; Wu et al., 2009).
Thecoloniccommensalmicroflorahasbeenshown toplayamajor
role in promoting expression of IL-17A, which triggers colorectal
tumorigenesis (Grivennikov et al., 2012). It has been proposed
that development of tumor-infiltrating CD4+ Th17 cells may be a
general feature in cancer patients (Su et al., 2010). Our data point
to the contribution of other IL-17-producing cells. Therefore, this
work furthers our general understanding of the role of immune
cells in the control of colorectal cancer development, which needs
to be taken into consideration in clinical oncology. In addition, this
workprovides a valuablepreclinicalmousemodel for the develop-
ment of new immunotherapy strategies.
EXPERIMENTAL PROCEDURES
Mice
Generation of TSSP-deficient (Prss16/) mice backcrossed on the C57BL/6
parental genetic background and their genotyping by PCR were described
previously (Gommeaux et al., 2009). Mice deficient for the TCR subunit
CD3-ε (CD3-ε delta5 mice devoid of T lymphocytes, referred as CD3 KO in
the text) were a kind gift of Marie Malissen (Malissen et al., 1995). Male mice
entered protocols at 8 weeks of age except for adoptive transfer (4 weeks
old). All mice were kept within the animal facilities and according to the policies
of the Laboratoire d’Exploration Fonctionnelle de Luminy (Marseille, France).
Tumor Induction
CAC tumors were induced as previously reported (Gommeaux et al., 2007).
Briefly, TSSP-deficient male mice and WT littermates (8–10 weeks old) were44 Cell Reports 10, 39–46, January 6, 2015 ª2015 The Authorsinjected i.p. with 12.5 mg/kg AOM (Sigma). After 5 days, 2.5% DSS (MP Bio-
medicals; molecular weight = 36,000–50,000 Da) was given in the drinking wa-
ter over 5 days, followed by 16 days of tap water. This cycle was repeated
twice (5 days of 2.5% DSS and 4 days of 2% DSS), and mice were sacrificed
10 days after the last cycle. When specified, mice were intravenously (i.v.)
injected with 2 mg of either anti-IL-17A antibody (LEAF purified anti-mouse
IL-17A from BioLegend) or control isotype (LEAF purified rat IgG1, k isotype
control from BioLegend) weekly during CAC protocol.
Induction and Analysis of Acute Colitis
Treatment with DSS leads to acute colonic inflammation with superficial ulcer-
ation, mucosal damage, and leukocyte infiltration. DSS is toxic to mucosal
epithelial cells, the eventual dysfunction of the mucosal barrier leading to
mucosal inflammation. Male mice (7–10 weeks old) were given 3.5% DSS in
their drinking water for 7 days, followed by water, only until sacrifice. Every
day during and after DSS administration, mice weremonitored for body weight
loss, pathological features (rectal bleeding and diarrhea), and survival. Body
weight was expressed as a percentage of the initial weight on day 0 of the pro-
tocol. Presence of diarrhea, rectal bleeding, and weight loss were separately
graded on a 0–3 scale (Gommeaux et al., 2007), and the sum of the three
values constitutes the disease activity index.
Morphological and Histological Analyses
Colons were removed, rinsed free of feces with PBS, cut open longitudinally,
carefully dried on blotting paper, weighed, measured, and photographed at
high resolution. For each colon individually, weight-to-length ratio was deter-
mined, in milligrams per millimeters of colon. For histochemical analysis, colon
samples were fixed flat in 4% formaldehyde at 4C overnight and paraffin
embedded as ‘‘Swiss rolls’’ containing the full-length organ. Five-micrometer-
thick sections were stained with hematoxylin and eosin for histopathological
assessment of colitis and tumors. Integrality of mounted stained sections sur-
faces were viewed on a Nikon microscope, and representative pictures are
shown. Proliferation (Ki67 immunostaining) and immunohistofluorescence ana-
lyses were performed as described in Supplemental Experimental Procedures.
Adoptive Transfer and Flow Cytometry
For adoptive transfer, total T (CD3+) cells, CD4+ cells, or CD8+ cells were pu-
rified from spleens by negative selection using EasySep negative selection kits
(STEMCELL Technologies). Four-week-old CD3 KO recipient male mice were
i.v. injected with 10–153 106 T cells (2:1 ratio when mixture of CD4+ and CD8+
cells) isolated from 8- to 10-week-old male donors. Blood cells were analyzed
4 weeks after adoptive transfer by staining with CD4, CD8a, and CD3ε specific
antibodies in fluorescence-activated cell sorting (FACS) buffer (PBS/3% fetal
calf serum [FCS]), and the CAC protocol was started the week after. At the
end of the CAC protocol, lymphocyte suspensions were prepared from
spleens and lymph nodes and stained with the specified antibodies (BD Bio-
sciences or BioLegend) after blocking of FcRgIII/II with a rat anti-mouse
CD16/CD32 monoclonal antibody (clone 2.4G2). Stained cells were analyzed
on a FACSCalibur flow cytometer (BD Biosciences), and data analysis was
performed using FlowJo software (Tree Star).
Purification and Analysis of Lamina Propria Lymphocytes (LPLs)
Purification of LPLs was performed as described previously (Weigmann
et al., 2007). Briefly, colons were cut into 0.5 cm pieces, washed in Hank’s
balanced salt solution (HBSS)/2% FCS, then incubated in HBSS/2 mM
EDTA at 37C under rotation twice (15 min then 30 min). Pieces were filtered
on 70 mm cell strainer then incubated in RPMI/10% FCS/1% HEPES contain-
ing 1 mg/ml collagenase 8 (Sigma) at 37C under rotation during 45 min or
1 hr when colons contained tumors to favor the liberation of TILs. Cells
were passed through a 70 mm cell strainer then isolated by centrifugation
with 40/90 Percoll (Sigma) gradient for 20 min at 1,000 3 g at 20C without
braking. Cells were then resuspended into FACS buffer and stained with fluo-
rochrome-labeled antibodies (BioLegend) specific for immune cells markers
(CD3+CD8+CD4 for T cells, CD4+FoxP3+IL-17A for Tregs and Th17,
Gr1+CD11b for granulocytes) after blocking of FcRgIII/II. For intracellular
staining (nuclear FoxP3 or cytoplasmic IL-17A), cells were fixed and permea-
bilized using Fix/Perm and Perm/Wash (Life Technologies). Stained cells
were analyzed on a MACSQuant VYB flow cytometer (Miltenyi Biotec), and
data analysis was performed using FlowJo software (Tree Star). Lymphoid
cells were gated on forward scatter/side scatter dot plots for CD4, CD8,
and Treg cell analysis; total viable cells were gated for granulocytes and
IL-17+ cell analysis.
Expression Analysis
Total RNA was isolated from frozen tissue samples with TRIzol reagent (Life
Technologies) according to the manufacturer’s instructions. Reverse tran-
scription of total RNA (2–5 mg) was realized using GoScript Reverse transcrip-
tion system with provided oligodeoxythymidine primers (Promega). cDNA
amplicons were amplified with specific primers (Table S1) and GoTaq qPCR
Master Mix kit (Promega) using a Mx3000P Stratagene device. For cytokine
expression analysis, each data point represents results obtained from at least
five entire colons made in triplicate.
Statistical Analyses
Results are expressed as the mean ± SD of results from at least two indepen-
dent experiments. Statistical analyses were performed via Student’s t test.
Study Approval
Care and manipulation of mice were performed in accordance with national
and European legislation on animal experimentation and were approved by
the Aix-Marseille University Institutional Animal Care and Use Committee.
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